| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.7 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.7 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |